Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells

Combination targeted therapy is commonly used to treat acute myeloid leukemia (AML) patients, particularly in refractory/relapse (RR) population. However, concerns have been raised regarding the safety and patient tolerance of combination chemotherapy. It is critical to choose the appropriate treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hui, Zheng, Qi-Li, Fang, Peng, Zhang, Jian, Zhang, Tuo, Liu, Wei, Guo, Min, Robinson, Christopher L., Chen, Shui-bing, Chen, Xiao-Ping, Chen, Fang-Ping, Zeng, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241777/
https://www.ncbi.nlm.nih.gov/pubmed/28098170
http://dx.doi.org/10.1038/srep40361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241777/
https://www.ncbi.nlm.nih.gov/pubmed/28098170
http://dx.doi.org/10.1038/srep40361

Ejemplares similares